• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Temporal trends in clinical outcomes after percutaneous coronary intervention: a systematic review of 66,327 patients from 25 all-comers trials.经皮冠状动脉介入治疗后临床结局的时间趋势:25 项全患者试验中 66327 例患者的系统评价。
EuroIntervention. 2022 Mar 18;17(16):1318-1329. doi: 10.4244/EIJ-D-21-00192.
2
Comparison of Clinical Outcomes Following Single versus Multivessel Percutaneous Coronary Intervention Using Biodegradable Polymer Coated Sirolimus-Eluting Stent in an All-comers Patient Population.在所有患者人群中使用生物可降解聚合物涂层西罗莫司洗脱支架进行单支血管与多支血管经皮冠状动脉介入治疗后的临床结果比较。
Cardiovasc Hematol Agents Med Chem. 2016;14(1):39-48. doi: 10.2174/1871525714666151120111839.
3
Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).在冠状动脉疾病中,依维莫司洗脱支架与紫杉醇洗脱支架的荟萃分析:SPIRIT 临床试验计划的最终 3 年结果(在治疗新发病变的患者中,使用依维莫司洗脱冠状动脉支架系统治疗的西里斯 V 依维莫司洗脱冠状动脉支架系统的临床评估)。
JACC Cardiovasc Interv. 2013 Sep;6(9):914-22. doi: 10.1016/j.jcin.2013.05.005.
4
A randomized comparison of platinum chromium-based everolimus-eluting stents versus cobalt chromium-based Zotarolimus-Eluting stents in all-comers receiving percutaneous coronary intervention: HOST-ASSURE (harmonizing optimal strategy for treatment of coronary artery stenosis-safety & effectiveness of drug-eluting stents & anti-platelet regimen), a randomized, controlled, noninferiority trial.随机比较全人群经皮冠状动脉介入治疗中使用基于铂铬的依维莫司洗脱支架与基于钴铬的佐他莫司洗脱支架:HOST-ASSURE(优化治疗冠状动脉狭窄策略的协调性研究-药物洗脱支架和抗血小板方案的安全性和有效性),一项随机、对照、非劣效性试验。
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt A):2805-16. doi: 10.1016/j.jacc.2014.04.013. Epub 2014 May 7.
5
Effect of Increasing Stent Length on 3-Year Clinical Outcomes in Women Undergoing Percutaneous Coronary Intervention With New-Generation Drug-Eluting Stents: Patient-Level Pooled Analysis of Randomized Trials From the WIN-DES Initiative.新一代药物洗脱支架经皮冠状动脉介入治疗中增加支架长度对女性患者 3 年临床结局的影响:WIN-DES 计划随机试验的患者水平汇总分析。
JACC Cardiovasc Interv. 2018 Jan 8;11(1):53-65. doi: 10.1016/j.jcin.2017.11.020.
6
The Role of Vascular Imaging in Guiding Routine Percutaneous Coronary Interventions: A Meta-Analysis of Bare Metal Stent and Drug-Eluting Stent Trials.血管成像在常规经皮冠状动脉介入治疗中的作用:金属裸支架和药物洗脱支架试验的荟萃分析。
Cardiovasc Ther. 2015 Dec;33(6):360-6. doi: 10.1111/1755-5922.12160.
7
First generation versus second generation drug-eluting stents for the treatment of bifurcations: 5-year follow-up of the LEADERS all-comers randomized trial.第一代与第二代药物洗脱支架治疗分叉病变:LEADERS全人群随机试验的5年随访
Catheter Cardiovasc Interv. 2016 Jun;87(7):E248-60. doi: 10.1002/ccd.26344. Epub 2015 Dec 9.
8
Complex vs. non-complex percutaneous coronary intervention with newer-generation drug-eluting stents: an analysis from the randomized BIOFLOW trials.新一代药物洗脱支架的复杂与非复杂经皮冠状动脉介入治疗:来自随机 BIOFLOW 试验的分析。
Clin Res Cardiol. 2022 Jul;111(7):795-805. doi: 10.1007/s00392-022-01994-4. Epub 2022 Feb 25.
9
Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.与含有不可降解聚合物的西罗莫司洗脱支架相比,含可生物降解聚合物的比伐卢定洗脱支架在冠状动脉疾病患者中具有更好的安全性和降低支架血栓形成的风险:LEADERS(雷帕霉素从不可降解到可降解涂层支架洗脱)随机、非劣效性试验的最终 5 年报告。
JACC Cardiovasc Interv. 2013 Aug;6(8):777-89. doi: 10.1016/j.jcin.2013.04.011.
10
5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents: Final Report of the DUTCH PEERS (TWENTE II) Trial.随机治疗所有患者的瑞波西利洗脱 Resolute Integrity 和依维莫司洗脱 PROMUS Element 冠状动脉支架 5 年结果:DUTCH PEERS(TWENTE II)试验的最终报告。
JACC Cardiovasc Interv. 2018 Mar 12;11(5):462-469. doi: 10.1016/j.jcin.2017.11.031.

引用本文的文献

1
Exploring the Impact of Beta-Blockers Post-Acute Myocardial Infarction in Patients with Preserved Ejection Fraction: A Meta-Analysis.探讨β受体阻滞剂对射血分数保留的急性心肌梗死后患者的影响:一项荟萃分析。
J Clin Med. 2025 Jun 4;14(11):3969. doi: 10.3390/jcm14113969.
2
Comparable clinical characteristics and outcomes of patients undergoing endovascular treatment for aorto-iliac or femoropopliteal lesions.接受主动脉-髂动脉或股腘动脉病变血管内治疗患者的可比临床特征和结局。
Cardiovasc Interv Ther. 2025 May 24. doi: 10.1007/s12928-025-01143-4.
3
A-kinase anchoring protein 1: an independent predictor of coronary artery disease.A激酶锚定蛋白1:冠状动脉疾病的独立预测因子。
BMC Cardiovasc Disord. 2025 Mar 7;25(1):156. doi: 10.1186/s12872-025-04613-y.
4
Adjustment of the ACEF score by the triglyceride glucose index improves the prediction of clinical outcomes in patients undergoing percutaneous coronary intervention.通过甘油三酯葡萄糖指数调整ACEF评分可改善经皮冠状动脉介入治疗患者临床结局的预测。
Cardiovasc Diabetol. 2024 Dec 18;23(1):440. doi: 10.1186/s12933-024-02534-2.
5
Beta-Blockers for Secondary Prevention following Myocardial Infarction in Patients Without Reduced Ejection Fraction or Heart Failure: An Updated Meta-Analysis.射血分数未降低或无心力衰竭的心肌梗死患者二级预防用β受体阻滞剂:一项更新的荟萃分析。
Eur J Prev Cardiol. 2024 Sep 20. doi: 10.1093/eurjpc/zwae298.
6
Plasma metabolomics reveals the shared and distinct metabolic disturbances associated with cardiovascular events in coronary artery disease.血浆代谢组学揭示了冠心病患者心血管事件相关的共同和独特的代谢紊乱。
Nat Commun. 2024 Jul 8;15(1):5729. doi: 10.1038/s41467-024-50125-2.
7
Clinical Background and Coronary Artery Lesions Characteristics in Japanese Patients With Acute Coronary Syndrome Suffering Major Bleeding.日本急性冠状动脉综合征患者发生严重出血时的临床背景及冠状动脉病变特征
Circ Rep. 2024 Feb 17;6(3):64-73. doi: 10.1253/circrep.CR-24-0003. eCollection 2024 Mar 8.
8
The impact of on-site cardiac surgical backup on clinical outcomes of acute coronary syndrome-analysis of the ACSIS national registry.现场心脏外科后备支持对急性冠状动脉综合征临床结局的影响——ACSIS国家注册研究分析
Front Cardiovasc Med. 2023 Sep 1;10:1207473. doi: 10.3389/fcvm.2023.1207473. eCollection 2023.
9
Persistent mortality and heart failure burden of anterior ST-segment elevation myocardial infarction following primary percutaneous coronary intervention: real-world evidence from the US Medicare Data Set.经皮冠状动脉介入治疗后前 ST 段抬高型心肌梗死患者持续的死亡率和心力衰竭负担:来自美国医疗保险数据集的真实世界证据。
BMJ Open. 2023 Jun 21;13(6):e070210. doi: 10.1136/bmjopen-2022-070210.
10
Early ACEI/ARB use and in-hospital outcomes of acute myocardial infarction patients with systolic blood pressure <100 mmHg and undergoing percutaneous coronary intervention: Findings from the CCC-ACS project.收缩压<100 mmHg且接受经皮冠状动脉介入治疗的急性心肌梗死患者早期使用血管紧张素转换酶抑制剂/血管紧张素Ⅱ受体阻滞剂及其院内结局:CCC-ACS项目的研究结果
Front Cardiovasc Med. 2022 Sep 29;9:1003442. doi: 10.3389/fcvm.2022.1003442. eCollection 2022.

本文引用的文献

1
Randomized Comparison of the Polymer-Free Biolimus-Coated BioFreedom Stent With the Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Orsiro Stent in an All-Comers Population Treated With Percutaneous Coronary Intervention: The SORT OUT IX Trial.随机比较聚合物自由的生物可吸收雷帕霉素洗脱紫杉醇 Orsiro 支架与超薄支架生物可降解聚合物西罗莫司洗脱 BioFreedom 支架在经皮冠状动脉介入治疗的所有患者中的疗效:SORT OUT IX 试验。
Circulation. 2020 Jun 23;141(25):2052-2063. doi: 10.1161/CIRCULATIONAHA.119.040241. Epub 2020 May 21.
2
Initial Invasive or Conservative Strategy for Stable Coronary Disease.稳定型冠心病的初始侵入性或保守治疗策略。
N Engl J Med. 2020 Apr 9;382(15):1395-1407. doi: 10.1056/NEJMoa1915922. Epub 2020 Mar 30.
3
Utilization and Outcomes of Measuring Fractional Flow Reserve in Patients With Stable Ischemic Heart Disease.稳定型缺血性心脏病患者测量血流储备分数的利用和结果。
J Am Coll Cardiol. 2020 Feb 4;75(4):409-419. doi: 10.1016/j.jacc.2019.10.060.
4
Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting.替格瑞洛单药治疗与药物洗脱冠状动脉支架置入后 1 个月双联抗血小板治疗的比较。
J Am Coll Cardiol. 2019 Nov 5;74(18):2223-2234. doi: 10.1016/j.jacc.2019.08.1038.
5
Everolimus-Eluting Versus Biolimus-Eluting Stents With Biodegradable Polymers in Unselected Patients Undergoing Percutaneous Coronary Intervention: A Randomized Noninferiority Trial With 1-Year Follow-Up (SORT OUT VIII Trial).无聚合物涂层依维莫司洗脱支架与生物可吸收聚合物涂层依维莫司洗脱支架治疗行经皮冠状动脉介入治疗的未选择患者的随机非劣效性试验:1 年随访(SORT OUT VIII 试验)。
JACC Cardiovasc Interv. 2019 Apr 8;12(7):624-633. doi: 10.1016/j.jcin.2018.12.036.
6
Safety and efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (TALENT): a prospective multicentre randomised controlled trial.载有西罗莫司的超小厚度冠状动脉支架治疗动脉粥样硬化性病变的安全性和有效性(TALENT):一项前瞻性多中心随机对照试验。
Lancet. 2019 Mar 9;393(10175):987-997. doi: 10.1016/S0140-6736(18)32467-X. Epub 2019 Feb 28.
7
Temporal trends in relative survival following percutaneous coronary intervention.经皮冠状动脉介入治疗后相对生存率的时间趋势。
BMJ Open. 2019 Feb 19;9(2):e024627. doi: 10.1136/bmjopen-2018-024627.
8
Randomized All-Comers Evaluation of a Permanent Polymer Zotarolimus-Eluting Stent Versus a Polymer-Free Amphilimus-Eluting Stent.随机全人群评价永久性聚合物佐他莫司洗脱支架与无聚合物安莫司他汀洗脱支架。
Circulation. 2019 Jan 2;139(1):67-77. doi: 10.1161/CIRCULATIONAHA.118.037707.
9
Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultrathin cobalt-chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, randomised non-inferiority trial.薄复合丝支架,耐用聚合物涂层(Resolute Onyx)与超薄钴铬支架,生物可吸收聚合物涂层(Orsiro)药物洗脱支架在所有伴有冠状动脉疾病的患者中的应用(BIONYX):一项国际性、单盲、随机非劣效性试验。
Lancet. 2018 Oct 6;392(10154):1235-1245. doi: 10.1016/S0140-6736(18)32001-4. Epub 2018 Sep 22.
10
Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trial.靶向治疗联合局部无内膜覆盖槽、低剂量西罗莫司洗脱、可生物降解聚合物冠状动脉支架(TARGET All Comers):一项多中心、开放标签、随机非劣效性试验。
Lancet. 2018 Sep 29;392(10153):1117-1126. doi: 10.1016/S0140-6736(18)31649-0. Epub 2018 Sep 3.

经皮冠状动脉介入治疗后临床结局的时间趋势:25 项全患者试验中 66327 例患者的系统评价。

Temporal trends in clinical outcomes after percutaneous coronary intervention: a systematic review of 66,327 patients from 25 all-comers trials.

机构信息

Department of Cardiovascular Medicine, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan.

Department of Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.

出版信息

EuroIntervention. 2022 Mar 18;17(16):1318-1329. doi: 10.4244/EIJ-D-21-00192.

DOI:10.4244/EIJ-D-21-00192
PMID:34602385
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9743235/
Abstract

BACKGROUND

With the improvements of percutaneous coronary intervention (PCI) technology and post-PCI patient management, several registry studies reported temporal trends in post-PCI clinical outcomes. However, their results are inconclusive, potentially reflecting region-specific trends, based on site-reported events without external validity.

AIMS

This study aimed to investigate temporal trends in post-PCI clinical outcomes in all-comers randomised controlled trials (RCTs) involving coronary stents.

METHODS

We performed a systematic review identifying RCTs comparing a clinical outcome as a primary endpoint among different coronary stents with an all-comers design and independent clinical event adjudication, extracting the study start year, patient baseline characteristics, and one- and five-year clinical outcomes. Temporal trends in clinical outcomes (cardiac death, myocardial infarction [MI], target lesion revascularisation [TLR], stent thrombosis [ST]) were assessed using random-effects meta-regression analyses, estimating the relationship between clinical outcomes and study start year.

RESULTS

Overall, 25 all-comers trials (51 device arms, 66,327 patients) conducted between 2003 and 2018 fulfilled the eligibility criteria. Random-effects meta-regression analysis revealed significant decreasing trends in one- and five-year cardiac death, one-year TLR, and five-year ST incidences (relative risk per 10-year increase: 0.69 [0.51-0.92], 0.66 [0.44-0.98], 0.60 [0.41-0.88], and 0.18 [0.07-0.44], respectively). There was no significant trend in myocardial infarction incidences.

CONCLUSIONS

This is the first attempt to clarify and quantify the temporal trends of post-PCI outcome incidence. The 15-year improvements in PCI therapy and post-therapeutic patient management are associated with reduced incidences of cardiac death and PCI-related adverse events.

摘要

背景

随着经皮冠状动脉介入治疗(PCI)技术和 PCI 后患者管理的进步,几项注册研究报告了 PCI 后临床结局的时间趋势。然而,他们的结果并不一致,可能反映了基于站点报告事件而没有外部有效性的特定地区的趋势。

目的

本研究旨在调查所有接受者随机对照试验(RCT)中 PCI 后临床结局的时间趋势,这些试验涉及冠状动脉支架。

方法

我们进行了一项系统评价,确定了 RCT,这些 RCT 比较了不同冠状动脉支架的临床结局作为主要终点,这些 RCT 采用了所有接受者设计和独立的临床事件评估,提取了研究开始年份、患者基线特征以及一年和五年的临床结局。使用随机效应荟萃回归分析评估临床结局(心脏死亡、心肌梗死[MI]、靶病变血运重建[TLR]、支架血栓形成[ST])的时间趋势,估计临床结局与研究开始年份之间的关系。

结果

共有 25 项所有接受者试验(51 个器械臂,66327 名患者)于 2003 年至 2018 年期间进行,符合入选标准。随机效应荟萃回归分析显示,一年和五年心脏死亡、一年 TLR 和五年 ST 发生率呈显著下降趋势(每 10 年增加的相对风险:0.69 [0.51-0.92]、0.66 [0.44-0.98]、0.60 [0.41-0.88]和 0.18 [0.07-0.44])。心肌梗死发生率无显著趋势。

结论

这是首次尝试澄清和量化 PCI 后结局发生率的时间趋势。15 年来 PCI 治疗和治疗后患者管理的改善与心脏死亡和 PCI 相关不良事件发生率的降低有关。